Synaptotagmin XIV: A Potential Drug Target and Biomarker (G255928)

Target Name: SYT14

NCBI ID: G255928

SYT14

Synaptotagmin XIV: A Potential Drug Target and Biomarker

Synaptotagmin XIV, also known as SX-14, is a protein that is expressed in the central nervous system (CNS) and has been identified as a potential drug target and biomarker.Synaptotagmin XIV is a transmembrane protein that is characterized by its unique structure, which consists of a long extracellular domain, a short intracellular domain, and a unique cytoplasmic region.

The cytoplasmic region of Synaptotagmin XIV is composed of a series of unique domains that give the protein its unique structure and function. The first domain is a N-terminal domain that is composed of a variety of amino acids that are involved in the protein's cytoplasmic localization. The second domain is a transmembrane domain that is composed of a unique combination of amino acids that is involved in the protein's transmembrane properties. The third domain is an intracellular domain that is composed of a variety of amino acids that are involved in the protein's intracellular localization and functions.

Synaptotagmin XIV has been shown to play a role in the regulation of a variety of cellular processes, including neurotransmitter release, synaptic plasticity, and stress response. One of the most significant findings related to Synaptotagmin XIV is its role in the regulation of neurotransmitter release. Synaptotagmin XIV has been shown to play a role in the regulation of the release of neurotransmitters, such as dopamine and GABA, from axons in the central nervous system.

In addition to its role in neurotransmitter release, Synaptotagmin XIV has also been shown to play a role in the regulation of synaptic plasticity. Synaptotagmin XIV has been shown to play a role in the regulation of synaptic plasticity in the brain, including the formation of new synapses and the modulation of synaptic strength.

Synaptotagmin XIV has also been shown to play a role in the regulation of stress response. Synaptotagmin XIV has been shown to play a role in the regulation of stress response in the brain, including the modulation of anxiety and depression-like behavior.

Given its unique structure and the variety of functions that have been shown to be involved in Synaptotagmin XIV, it is likely that the protein could be a valuable drug target. Additionally, given its role in a variety of cellular processes, including neurotransmitter release, synaptic plasticity, and stress response, it is likely that the protein could also be a valuable biomarker for a variety of neurological and psychiatric disorders.

In conclusion, Synaptotagmin XIV is a protein that has the potential to be a drug target and biomarker. Its unique structure and the variety of functions that have been shown to be involved in the protein make it an attractive target for drug development. Further research is needed to fully understand the role of Synaptotagmin XIV in the regulation of cellular processes and to determine its potential as a drug target and biomarker.

Protein Name: Synaptotagmin 14

Functions: May be involved in the trafficking and exocytosis of secretory vesicles in non-neuronal tissues. Is Ca(2+)-independent

The "SYT14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SYT14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets